Biotech Industry Examiner

Menu
Menu
subscribe now
Search
A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see

A one-time gene edit for cholesterol: promise, price and the risks we can’t yet see

Early data from a tiny trial suggest that a single

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

Cholesterol Rewritten: Verve’s Base Editing Therapy May Disrupt a $20B Market

High cholesterol has long been a silent threat lurking in

Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market

Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

Chai Discovery’s $130m bet: can “CAD for molecules” make biologics faster and cheaper?

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

From Cow-Free Dairy to Human Milk 2.0: Biotechs Race to Brew Breast Milk Proteins

MOST POPULAR

News

The GLP-1 pill arrives: Novo’s oral Wegovy reshapes the obesity market
The obesity wars go to court: Pfizer says Novo’s Metsera bid is a moat, not a merger
Galapagos quits cell therapy. Europe’s CGT reckoning begins.
Dermatology’s next play: bispecifics that shut down OX40L and TNF

Funding

Aging Science

The explainable aging clock regulators might actually like
Impact of Space Travel on Immune Function and Potential Countermeasures
Debate Highlights: Can Aging Be Halted or Reversed? Experts Weigh In
Epigenetic Stability Linked to Lifespan in Mammals, Research Show

Genomics

M&A & Partnerships

Novartis’s $1.7bn Alzheimer’s bet: the real battleground is the blood–brain barrier
Sanofi’s $2.2bn Dynavax deal — and the quiet power of adult vaccines
Pfizer’s $4.9bn Metsera bet: can amylin finally tame GLP-1’s ‘GI tax’?
More Than a Shot: Sanofi’s Vicebio Deal Shows the Power of Platform Biotech

Biotech Stocks

Psychology

Innovative Study on Addiction by Mount Sinai and Rockefeller University

Copyright © Industry Examiner 2025 . All rights reserved.

Industry Examiner LLC 166 Geary St. STE 1500 #2640, San Francisco, CA 94108

Facebook Twitter Linkedin Link
Scroll to Top